Effects_NNS of_IN Various_JJ Test_NP Media_NP on_IN the_DT Activities_NNS of_IN 21_CD Antimicrobial_JJ Agents_NNS against_IN Haemophilus_NP influenzae_NP As_IN considerable_JJ variation_NN in_IN the_DT antimicrobial_JJ susceptibility_NN of_IN Haemophilus_NP influenzae_NP has_VBZ been_VBN reported_VBN ,_, the_DT effects_NNS of_IN various_JJ test_NN media_NNS on_IN the_DT susceptibility_NN of_IN H._NP influenzae_NP were_VBD studied_VBN ._SENT MICs_NNS were_VBD determined_VBN by_IN three_CD laboratories_NNS for_IN 21_CD antimicrobial_JJ agents_NNS against_IN a_DT panel_NN of_IN 100_CD selected_JJ isolates_NNS ._SENT Testing_NN was_VBD performed_VBN using_VBG a_DT reference_NN NCCLS_VBZ frozen_JJ broth_NN microdilution_NN method_NN with_IN Haemophilus_NP test_NN medium_NN (_( HTM_NP )_) broth_NN and_CC dried_VBD commercial_JJ MIC_JJ trays_NNS rehydrated_VBN with_IN the_DT following_VBG media_NNS :_: in-house_JJ and_CC commercially_RB prepared_VBN HTM_NP broth_NN ,_, Mueller-Hinton_NP broth_NN with_IN 2_CD %_NN lysed_VBD horse_NN blood_NN and_CC NAD_NN ,_, IsoSensitest_JJ broth_NN with_IN 2_CD %_NN lysed_VBD horse_NN blood_NN and_CC NAD_NN ,_, and_CC IsoSensitest_JJ broth-based_JJ HTM_NP ._SENT Overall_RB ,_, all_DT results_NNS were_VBD very_RB reproducible_JJ ,_, with_IN the_DT MIC_NN at_IN which_WDT 50_CD %_NN of_IN the_DT isolates_NNS tested_VBN are_VBP inhibited_VBN (_( MIC50_NP )_) ,_, MIC90_NP ,_, and_CC geometric_JJ mean_JJ MIC_NN being_VBG within_IN one_CD doubling_NN dilution_NN by_IN all_DT six_CD methods_NNS and_CC at_IN all_DT three_CD testing_NN centers_NNS for_IN 15_CD of_IN the_DT 21_CD agents_NNS tested_VBD ._SENT Interlaboratory_JJ differences_NNS were_VBD more_RBR marked_VBN than_IN intralaboratory_JJ differences_NNS or_CC differences_NNS among_IN media_NNS ._SENT Cefprozil_NP ,_, cefaclor_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN results_NNS differed_VBD the_DT most_JJS ,_, while_IN results_NNS for_IN ampicillin_NN ,_, amoxicillin-clavulanic_JJ acid_NN ,_, cefdinir_NN ,_, cefixime_NN ,_, ceftriaxone_NN ,_, and_CC clarithromycin_NN were_VBD the_DT most_RBS reproducible_JJ ._SENT However_RB ,_, these_DT variations_NNS in_IN results_NNS caused_VBD considerable_JJ differences_NNS in_IN susceptibility_NN rates_NNS for_IN agents_NNS for_IN which_WDT NCCLS_NP susceptible_JJ breakpoints_NNS were_VBD close_JJ to_TO the_DT geometric_JJ mean_JJ MIC_NN ,_, particularly_RB for_IN cefaclor_NN and_CC cefprozil_NN ._SENT This_DT was_VBD much_RB less_JJR of_IN a_DT problem_NN when_WRB pharmacokinetic-pharmacodynamic_JJ breakpoints_NNS were_VBD used_VBN ._SENT Reproducible_JJ susceptibility_NN results_NNS were_VBD obtained_VBN for_IN a_DT wide_JJ range_NN of_IN agents_NNS against_IN H._NP influenzae_NP in_IN three_CD laboratories_NNS using_VBG a_DT variety_NN of_IN media_NNS that_WDT support_VBP the_DT growth_NN of_IN this_DT fastidious_JJ species_NN ._SENT Assessment_NN of_IN the_DT susceptibility_NN of_IN Haemophilus_NP influenzae_NP to_TO various_JJ antimicrobial_JJ agents_NNS is_VBZ relatively_RB easy_JJ for_IN agents_NNS for_IN which_WDT defined_VBD resistance_NN mechanisms_NNS are_VBP known_VBN and_CC which_WDT result_NN in_IN high-level_JJ resistance_NN ,_, such_JJ as_IN the_DT activities_NNS of_IN ampicillin_NN and_CC amoxicillin_NN against_IN beta-lactamase-producing_NN strains_NNS compared_VBN to_TO those_DT against_IN beta-lactamase-negative_JJ strains_NNS ._SENT When_WRB bimodal_JJ MIC_JJ populations_NNS are_VBP found_VBN ,_, susceptible_JJ and_CC resistant_JJ strains_NNS can_MD be_VB readily_RB differentiated_VBN ,_, particularly_RB if_IN the_DT MICs_NN of_IN susceptible_JJ strains_NNS are_VBP below_RB clinically_RB achievable_JJ levels_NNS of_IN the_DT agents_NNS ._SENT However_RB ,_, this_DT is_VBZ not_RB the_DT case_NN for_IN many_JJ agents_NNS for_IN which_WDT unimodal_JJ MIC_JJ distributions_NNS are_VBP found_VBN and_CC strains_NNS against_IN which_WDT the_DT MICs_NNS are_VBP higher_JJR are_VBP rare_JJ or_CC absent_JJ ._SENT This_DT circumstance_NN is_VBZ further_RBR complicated_VBN by_IN the_DT fact_NN that_IN MIC_JJ ranges_NNS may_MD include_VB values_NNS that_WDT are_VBP close_JJ to_TO clinically_RB achievable_JJ levels_NNS and/or_CC include_VBP MIC_JJ breakpoint_NN concentrations_NNS ._SENT Examples_NNS of_IN such_JJ agents_NNS include_VBP amoxicillin-clavulanate_NN ,_, cefuroxime_NN ,_, azithromycin_NP ,_, erythromycin_NN ,_, and_CC clarithromycin_NN ._SENT For_IN the_DT two_CD beta-lactam_NN examples_NNS ,_, the_DT situation_NN is_VBZ further_RBR complicated_VBN by_IN the_DT fact_NN that_IN strains_NNS for_IN which_WDT the_DT MICs_NNS are_VBP at_IN the_DT high_JJ end_NN of_IN the_DT distribution_NN may_MD have_VB non-beta-lactamase-mediated_JJ resistance_NN due_JJ to_TO altered_JJ penicillin-binding_NN proteins_NNS or_CC may_MD be_VB spheroplast-producing_JJ strains_NNS ._SENT Considerable_JJ variation_NN in_IN the_DT resistance_NN rates_NNS of_IN various_JJ agents_NNS against_IN H._NP influenzae_NP has_VBZ been_VBN reported_VBN ._SENT For_IN example_NN ,_, the_DT resistance_NN rates_NNS for_IN amoxicillin-clavulanate_NN varied_VBN from_IN 0_CD %_NN in_IN a_DT large_JJ international_JJ study_NN of_IN 2,718_CD strains_NNS to_TO 4.5_CD %_NN in_IN a_DT U.S._NP study_NN of_IN 1,539_CD strains_NNS ._SENT Similarly_RB ,_, the_DT resistance_NN rates_NNS for_IN cefuroxime_NN varied_VBN from_IN 3.2_CD to_TO 6.4_CD %_NN ._SENT Although_IN these_DT resistance_NN rates_NNS are_VBP low_JJ and_CC differences_NNS between_IN studies_NNS are_VBP not_RB very_RB large_JJ ,_, the_DT susceptible_JJ breakpoint_NN for_IN these_DT agents_NNS (_( <=4_JJ mug/ml_NN )_) is_VBZ close_JJ to_TO the_DT MICs_NN of_IN these_DT agents_NNS at_IN which_WDT 90_CD %_NN of_IN the_DT isolates_NNS tested_VBN are_VBP inhibited_VBN (_( MIC90s_NP )_) (_( 1_CD to_TO 8_CD mug/ml_NN )_) ,_, and_CC normal_JJ population_NN distributions_NNS could_MD account_VB for_IN some_DT MICs_NN being_VBG in_IN the_DT resistant_JJ range_NN ._SENT This_DT study_NN examined_VBD the_DT effects_NNS of_IN various_JJ media_NNS on_IN the_DT susceptibility_NN of_IN this_DT species_NN to_TO a_DT wide_JJ range_NN of_IN antimicrobial_JJ agents_NNS ,_, using_VBG media_NNS that_WDT would_MD be_VB acceptable_JJ in_IN a_DT large_JJ number_NN of_IN countries_NNS ._SENT The_DT results_NNS are_VBP compared_VBN with_IN those_DT of_IN the_DT reference_NN NCCLS_NP method_NN using_VBG Haemophilus_NP test_NN medium_NN (_( HTM_NP )_) in_IN frozen_JJ microdilution_NN trays_NNS ._SENT Isolates_NNS ._SENT |_SYM The_DT isolates_NNS tested_VBN were_VBD 100_CD untypeable_JJ H._NP influenzae_NP isolates_VBZ from_IN stock_NN cultures_NNS which_WDT have_VBP been_VBN used_VBN for_IN the_DT validation_NN of_IN MIC_JJ plates_NNS from_IN several_JJ surveillance_NN studies_NNS ._SENT Of_IN the_DT 100_CD isolates_NNS ,_, 43_CD were_VBD beta-lactamase_NN positive_JJ and_CC 4_CD were_VBD beta-lactamase_NN negative_JJ and_CC ampicillin_NN resistant_NN ._SENT Antimicrobial_JJ agents_NNS ._SENT |_SYM A_DT total_NN of_IN 21_CD antimicrobial_JJ agents_NNS were_VBD tested_VBN ,_, consisting_VBG of_IN 9_CD beta-lactam_NN agents_NNS (_( ampicillin_NP ,_, amoxicillin_NP ,_, amoxicillin-clavulanic_JJ acid_NN ,_, ceftriaxone_NN ,_, cefuroxime_NN ,_, cefaclor_NN ,_, cefixime_NN ,_, cefprozil_NN ,_, and_CC cefdinir_NN )_) ,_, 3_CD macrolide_NN agents_NNS (_( azithromycin_NP ,_, clarithromycin_NN ,_, and_CC erythromycin_NN )_) ,_, 6_CD fluoroquinolone_JJ agents_NNS (_( ciprofloxacin_NP ,_, gemifloxacin_NP ,_, grepafloxacin_NP ,_, levofloxacin_NP ,_, ofloxacin_NN and_CC trovafloxacin_NN )_) ,_, chloramphenicol_NN ,_, doxycycline_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN ._SENT MIC_JJ methods_NNS ._SENT |_SYM All_DT strains_NNS were_VBD tested_VBN with_IN frozen_JJ trays_NNS utilizing_VBG the_DT NCCLS_NP broth_NN microdilution_NN method_NN with_IN in-house-prepared_JJ HTM_NP (_( frozen_VBN MH_NP HTM_NP [_SYM see_VBP below_RB ]_SYM )_) and_CC with_IN dried_VBN commercial_JJ MIC_JJ trays_NNS (_( Trek_NP Diagnostics_NP ,_, Westlake_NP ,_, Ohio_NP )_) rehydrated_VBD with_IN five_CD different_JJ media_NNS ._SENT Three_CD different_JJ testing_NN sites_NNS participated_VBD in_IN the_DT study_NN ._SENT Frozen_JJ MH_NP HTM_NP was_VBD tested_VBN at_IN Case_NP Western_NP Reserve_NP University_NP ,_, Cleveland_NP ,_, Ohio_NP ,_, while_IN the_DT dried_VBN commercial_JJ trays_NNS were_VBD tested_VBN at_IN all_DT three_CD sites_NNS ._SENT For_IN the_DT dried_VBN commercial_JJ trays_NNS ,_, all_RB of_IN the_DT sites_NNS used_VBD the_DT same_JJ batch_NN of_IN in-house_JJ HTM_NP (_( MH_NP HTM_NP )_) ,_, which_WDT was_VBD prepared_VBN by_IN the_DT investigators_NNS at_IN Case_NP Western_NP Reserve_NP University_NP using_VBG Mueller-Hinton_NP broth_NN base_NN (_( Difco_NP )_) ,_, 0.5_CD %_NN yeast_NN extract_NN (_( Difco_NP )_) ,_, 15_CD mug_NN of_IN NAD_NN per_IN ml_NN ,_, and_CC 15_CD mug_NN of_IN hematin_NN (_( Sigma_NP )_) per_IN ml_NN ._SENT Case_NP Western_NP Reserve_NP University_NP (_( site_NN 1_CD )_) and_CC M._NP S._NP Hershey_NP Medical_NP Center_NP ,_, Hershey_NP ,_, Pa._NP (_( site_NN 2_CD )_) also_RB tested_VBD the_DT strains_NNS with_IN Mueller-Hinton_NP broth_NN (_( Trek_NP Diagnostics_NP )_) supplemented_VBD with_IN 2_CD %_NN lysed_VBD horse_NN blood_NN (_( Cleveland_NP Scientific_NP ,_, Bath_NP ,_, Ohio_NP )_) and_CC 15_CD mug_NN of_IN NAD/ml_NP (_( MH_NP LHB_NP NAD_NN )_) ._SENT In_IN addition_NN ,_, site_NN 1_CD tested_VBD the_DT strains_NNS with_IN a_DT commercial_JJ formulation_NN of_IN HTM_NP broth_NN (_( PML_NP ,_, Tualatin_NP ,_, Oreg_NP ._SENT )_) (_( PML_NP HTM_NP )_) ._SENT GR_NP Micro_NP ,_, London_NP ,_, United_NP Kingdom_NP (_( site_NN 3_CD )_) also_RB used_VBD IsoSensitest_NP Broth_NP (_( Oxoid_NP Ltd._NP ,_, Basingstoke_NP ,_, United_NP Kingdom_NP )_) supplemented_VBD with_IN 2_CD %_NN lysed_VBD horse_NN blood_NN (_( TCS_JJ Microbiology_NN ,_, Botolph_NP Claydon_NP ,_, United_NP Kingdom_NP )_) and_CC 15_CD mug_NN of_IN NAD_NN (_( Sigma-Aldrich_NP UK_NP Ltd._NP ,_, Poole_NP ,_, United_NP Kingdom)/ml_NP (_( IST_NP LHB_NP NAD_NN )_) and_CC IsoSensitest_JJ broth-based_JJ HTM_NP (_( IsoSensitest_JJ broth_NN supplemented_VBN with_IN 15_CD mug_NN of_IN NAD_NN per_IN ml_NN ,_, 0.5_CD %_NN yeast_NN extract_NN [_SYM Oxoid_NP Ltd._NP ]_SYM ,_, and_CC 15_CD mug_NN of_IN hematin_NN [_SYM Oxoid_NP Ltd._NP ]_SYM per_FW ml_NP )_) (_( IST_NP HTM_NP )_) ._SENT Inoculum_NN checks_NNS were_VBD performed_VBN on_IN all_DT strains_NNS ,_, and_CC quality_NN control_NN strains_NNS (_( H._NP influenzae_NP ATCC_NP 49247_CD and_CC 49766_CD and_CC Escherichia_NP coli_NNS ATCC_NP 35218_CD )_) were_VBD included_VBN in_IN each_DT testing_NN run_NN ._SENT The_DT results_NNS were_VBD accepted_VBN if_IN inocula_NNS were_VBD in_IN the_DT range_NN of_IN 3_CD x_NN 105_CD to_TO 7_CD x_SYM 105_CD CFU/ml_NP and_CC the_DT MICs_NP for_IN the_DT quality_NN control_NN strains_NNS were_VBD within_IN published_VBN limits_NNS ._SENT Data_NP analysis_NN ._SENT |_SYM Geometric_NP mean_VB MICs_NP ,_, MIC50s_NP ,_, MIC90s_NP ,_, and_CC standard_JJ deviations_NNS for_IN each_DT method_NN ,_, based_VBN on_IN the_DT doubling-dilution_NN (_( i.e._FW ,_, log2_JJ )_) values_NNS ,_, were_VBD determined_VBN for_IN antimicrobial_JJ agents_NNS with_IN unimodal_JJ distributions_NNS and_CC on-scale_JJ endpoints_NNS for_IN >90_JJ %_NN of_IN the_DT strains_NNS ._SENT Ampicillin_NP ,_, amoxicillin_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN means_NNS were_VBD not_RB calculated_VBN because_IN of_IN bimodal_JJ distributions_NNS ._SENT Results_NNS for_IN all_DT methods_NNS were_VBD compared_VBN to_TO the_DT results_NNS for_IN frozen_JJ MH_NP HTM_NP ,_, and_CC doubling-dilution_NN differences_NNS were_VBD calculated_VBN ._SENT Susceptibility_NN rates_NNS were_VBD calculated_VBN based_VBN on_IN both_DT NCCLS_NP and_CC pharmacokinetic-pharmacodynamic_JJ (_( PK-PD_JJ )_) breakpoints_NNS ._SENT The_DT PK-PD_JJ breakpoints_NNS were_VBD based_VBN on_IN standard_JJ dosing_VBG regimens_NNS and_CC criteria_NNS appropriate_JJ to_TO each_DT agent_NN ._SENT For_IN beta-lactams_NNS ,_, erythromycin_NN ,_, and_CC clarithromycin_NN ,_, these_DT breakpoints_NNS were_VBD based_VBN on_IN drug_NN concentrations_NNS in_IN serum_NN present_JJ for_IN 40_CD to_TO 50_CD %_NN of_IN the_DT dosing_VBG interval_NN ,_, while_IN for_IN azithromycin_NN ,_, fluoroquinolones_NNS ,_, and_CC doxycycline_NN ,_, they_PP were_VBD based_VBN on_IN 24-h_JJ area_NN under_IN the_DT concentration-time_JJ curve/MIC_JJ ratios_NNS exceeding_VBG 25_CD ._SENT For_IN trimethoprim-sulfamethoxazole_NN ,_, the_DT NCCLS_NP breakpoint_NN was_VBD used_VBN ,_, as_IN the_DT PK-PD_JJ breakpoint_NN was_VBD not_RB available_JJ and_CC the_DT NCCLS_NP breakpoint_NN had_VBD been_VBN validated_VBN in_IN bacteriologic_JJ outcome_NN otitis_NN media_NNS studies_NNS ._SENT The_DT data_NNS were_VBD also_RB analyzed_VBN statistically_RB using_VBG several_JJ approaches_NNS ,_, with_IN the_DT frozen_JJ MH_NP HTM_NP as_IN the_DT reference_NN method_NN where_WRB applicable_JJ ._SENT First_RB ,_, the_DT data_NNS were_VBD examined_VBN with_IN generalized_VBN estimating_NN equations_NNS (_( GEE_NP )_) (_( SAS_NP ,_, Cary_NP ,_, N.C._NP )_) ,_, a_DT method_NN of_IN multiple_JJ regression_NN analysis_NN of_IN the_DT entire_JJ data_NN set_NN ,_, which_WDT was_VBD used_VBN to_TO assess_VB overall_JJ differences_NNS between_IN test_NN sites_NNS and_CC methods_NNS ._SENT GEE_NN methodology_NN was_VBD chosen_VBN because_IN it_PP could_MD handle_VB the_DT lack_NN of_IN independence_NN among_IN the_DT observations_NNS caused_VBN by_IN the_DT same_JJ isolates_NNS being_VBG analyzed_VBN multiple_JJ times_NNS ._SENT In_IN effect_NN ,_, each_DT isolate_NN created_VBD a_DT family_NN of_IN related_JJ observations_NNS ._SENT Since_IN there_EX will_MD be_VB more_JJR variability_NN in_IN MICs_NP across_IN isolates_NNS than_IN across_IN methods_NNS for_IN a_DT particular_JJ isolate_NN ,_, it_PP is_VBZ important_JJ to_TO use_VB analysis_NN methods_NNS that_WDT recognize_VBP the_DT relationship_NN of_IN the_DT observations_NNS ._SENT The_DT GEE_NP methodology_NN can_MD be_VB used_VBN to_TO simultaneously_RB examine_VB the_DT effects_NNS of_IN method_NN and_CC sites_NNS ,_, obtaining_VBG an_DT estimated_JJ regression_NN coefficient_NN for_IN each_DT individual_JJ effect_NN variable_NN ._SENT Since_IN all_PDT the_DT effects_NNS were_VBD categorical_JJ variables_NNS ,_, each_DT effect_NN would_MD be_VB measured_VBN as_IN a_DT difference_NN from_IN a_DT reference_NN method_NN and_CC site_NN ._SENT Second_JJ ,_, sequential_JJ paired_VBN t_NN tests_NNS were_VBD performed_VBN to_TO compare_VB data_NN sets_NNS ,_, using_VBG the_DT frozen_JJ MH_NP HTM_NP as_IN the_DT reference_NN method_NN ._SENT This_DT analysis_NN was_VBD repeated_VBN using_VBG the_DT site_NN 1_CD MH_NP HTM_NP as_IN the_DT standard_NN ._SENT Since_IN the_DT MH_NP HTM_NP was_VBD prepared_VBN at_IN site_NN 1_CD and_CC distributed_VBN to_TO each_DT of_IN the_DT other_JJ testing_NN sites_NNS ,_, it_PP provided_VBD a_DT standard_NN for_IN measuring_VBG both_DT methodological_JJ and_CC within-site_JJ differences_NNS ._SENT Consequently_RB ,_, paired-t-test_NN analysis_NN was_VBD also_RB used_VBN to_TO examine_VB within-laboratory_JJ differences_NNS using_VBG each_DT site_NN 's_POS MH_NP HTM_NP results_NNS as_IN the_DT reference_NN method_NN ._SENT To_TO account_VB for_IN potential_JJ type_NN 1_CD error_NN resulting_VBG from_IN the_DT multiple_JJ t_NN tests_NNS employed_VBN ,_, a_DT Bonferroni_NP correction_NN was_VBD used_VBN ,_, requiring_VBG a_DT critical_JJ P_NN value_NN of_IN <0.0003_NN for_IN statistical_JJ significance_NN ._SENT Third_JJ ,_, the_DT data_NNS were_VBD examined_VBN for_IN overall_JJ mean_JJ population_NN differences_NNS using_VBG the_DT t_NN distribution_NN ,_, since_IN the_DT test_NN sample_NN population_NN MICs_NNS were_VBD normally_RB distributed_VBN with_IN similar_JJ variances_NNS ._SENT While_IN this_DT method_NN is_VBZ not_RB appropriate_JJ for_IN testing_VBG dependent_JJ data_NNS ,_, it_PP was_VBD thought_VBN to_TO provide_VB some_DT useful_JJ information_NN ,_, since_IN population_NN mean_VBP data_NNS are_VBP used_VBN in_IN microbial_JJ surveillance_NN studies_NNS and_CC repeated_JJ testing_NN of_IN the_DT same_JJ sample_NN would_MD be_VB expected_VBN to_TO regress_VB to_TO the_DT mean_NN ._SENT The_DT laboratory_NN methods_NNS examined_VBN in_IN this_DT study_NN are_VBP those_DT that_WDT would_MD likely_RB be_VB used_VBN in_IN large-scale_JJ surveillance_NN ._SENT The_DT critical_JJ value_NN used_VBN for_IN this_DT testing_NN was_VBD that_IN corresponding_JJ to_TO a_DT P_NN value_NN of_IN <0.0003_NN ._SENT The_DT robustness_NN of_IN some_DT of_IN the_DT statistical_JJ differences_NNS found_VBN was_VBD tested_VBN by_IN adjusting_VBG the_DT data_NNS by_IN +-0.25-_NN ,_, 0.5-_CD ,_, 0.75-_CD ,_, and_CC 1-doubling-dilution_JJ differences_NNS ._SENT Since_IN a_DT one-doubling-dilution_NN difference_NN is_VBZ considered_VBN an_DT acceptable_JJ level_NN of_IN sample_NN reproducibility_NN in_IN MIC_JJ testing_NN ,_, this_DT analysis_NN was_VBD performed_VBN to_TO determine_VB whether_IN adjusting_VBG the_DT data_NNS incrementally_RB within_IN the_DT one-dilution_NN range_NN would_MD effect_VB statistical_JJ significance_NN ._SENT The_DT percentages_NNS of_IN MICs_NP within_IN one_CD and_CC two_CD dilutions_NNS of_IN the_DT frozen_JJ reference_NN values_NNS were_VBD calculated_VBN ._SENT The_DT differences_NNS between_IN sites_NNS and_CC methods_NNS were_VBD examined_VBN by_IN the_DT binomial_JJ test_NN for_IN proportions_NNS for_IN both_DT one-_NN and_CC two-dilution_NN differences_NNS ._SENT The_DT differences_NNS in_IN agreement_NN with_IN the_DT frozen_JJ reference_NN values_NNS were_VBD examined_VBN directly_RB for_IN each_DT site-method_NN combination_NN ,_, as_RB well_RB as_IN for_IN methods_NNS within_IN each_DT site_NN ,_, with_IN the_DT site-specific_JJ MH_NP HTM_NP difference_NN from_IN frozen_JJ reference_NN values_NNS used_VBN as_IN the_DT baseline_NN for_IN these_DT comparisons_NNS ._SENT The_DT geometric_JJ mean_JJ MICs_NNS were_VBD within_IN one_CD doubling_NN dilution_NN by_IN all_DT six_CD methods_NNS and_CC at_IN all_DT three_CD testing_NN centers_NNS for_IN all_DT antimicrobial_JJ agents_NNS except_IN azithromycin_NN ,_, cefaclor_NN ,_, cefprozil_NN ,_, gemifloxacin_NP ,_, grepafloxacin_NN ,_, and_CC levofloxacin_NN ._SENT At_IN least_JJS 90_CD %_NN of_IN MICs_NP by_IN all_DT six_CD methods_NNS and_CC at_IN all_DT three_CD testing_NN centers_NNS were_VBD within_IN two_CD doubling_NN dilutions_NNS compared_VBN with_IN the_DT frozen_JJ reference_NN except_IN for_IN amoxicillin_NN with_IN IST_NP HTM_NP at_IN site_NN 3_CD ;_: cefuroxime_NN and_CC ampicillin_NN with_IN IST_NP LHB_NP NAD_NN at_IN site_NN 3_CD ;_: cefaclor_NN and_CC cefprozil_NN with_IN in-house_JJ HTM_NN at_IN site_NN 2_CD ,_, MH_NP LHB_NP NAD_NN at_IN site_NN 2_CD ,_, IST_NP HTM_NP at_IN site_NN 3_CD ,_, and_CC IST_NP LHB_NP NAD_NN at_IN site_NN 3_CD ;_: gemifloxacin_NN with_IN MH_NP LHB_NP NAD_NN at_IN sites_NNS 1_CD and_CC 2_CD ;_: and_CC trimethoprim-sulfamethoxazole_NN with_IN in-house_JJ HTM_NN at_IN site_NN 3_CD ,_, PML_NP HTM_NP at_IN site_NN 1_CD ,_, MH_NP LHB_NP NAD_NN at_IN site_NN 2_CD ,_, and_CC IST_NP LHB_NP NAD_NN at_IN site_NN 3_CD ._SENT An_DT analysis_NN of_IN the_DT differences_NNS by_IN antimicrobial_JJ agent_NN demonstrates_VBZ that_IN the_DT cefprozil_NN ,_, cefaclor_NN ,_, and_CC trimethoprim-sulfamethoxazole_NN results_NNS differed_VBD the_DT most_JJS ._SENT The_DT cefaclor_NN and_CC cefprozil_NN results_NNS for_IN sites_NNS 2_CD and_CC 3_CD were_VBD one_CD to_TO two_CD dilutions_NNS lower_JJR than_IN those_DT for_IN site_NN 1_CD ._SENT The_DT trimethoprim-sulfamethoxazole_NN results_NNS were_VBD not_RB reproducible_JJ within_IN each_DT laboratory_NN at_IN MICs_NP of_IN <0.5_JJ mug/ml_NN ._SENT The_DT results_NNS for_IN erythromycin_NN and_CC azithromycin_NN for_IN all_DT media_NNS were_VBD one_CD to_TO two_CD dilutions_NNS lower_JJR than_IN those_DT for_IN frozen_JJ MH_NP HTM_NP ;_: this_DT was_VBD seen_VBN more_RBR frequently_RB with_IN erythromycin_NN than_IN with_IN azithromycin_NN ._SENT Clarithromycin_NN agreement_NN with_IN the_DT frozen_JJ reference_NN method_NN was_VBD very_RB good_JJ for_IN all_DT media_NNS and_CC only_RB showed_VBD very_RB slight_JJ differences_NNS from_IN the_DT frozen_JJ reference_NN method_NN (_( MICs_NP in_RB dried_VBD trays_NNS were_VBD lower_JJR than_IN those_DT in_IN frozen_JJ MH_NP HTM_NP trays_NNS )_) ._SENT The_DT fluoroquinolone_JJ results_NNS (_( with_IN the_DT exception_NN of_IN ciprofloxacin_NN and_CC ofloxacin_NN )_) for_IN all_DT media_NNS in_IN the_DT dried_VBN trays_NNS were_VBD lower_JJR (_( one_CD to_TO two_CD dilutions_NNS )_) than_IN those_DT in_IN the_DT frozen_JJ MH_NP HTM_NP trays_NNS ._SENT The_DT majority_NN of_IN fluoroquinolone_NN results_NNS were_VBD at_IN very_RB low_JJ MICs_NN of_IN <0.03_JJ mug/ml_NN ,_, which_WDT may_MD explain_VB the_DT variation_NN in_IN results_NNS ._SENT The_DT gemifloxacin_NN and_CC grepafloxacin_NN MH_NP LHB_NP NAD_NN results_NNS at_IN sites_NNS 1_CD and_CC 2_CD were_VBD lower_JJR by_IN one_CD dilution_NN than_IN those_DT of_IN HTM-_NP and_CC IsoSensitest-based_JJ media_NNS ._SENT The_DT results_NNS for_IN ampicillin_NN ,_, amoxicillin-clavulanic_JJ acid_NN ,_, cefdinir_NN ,_, cefixime_NN ,_, ceftriaxone_NN ,_, ciprofloxacin_NP ,_, clarithromycin_NN ,_, and_CC ofloxacin_NN were_VBD the_DT most_RBS reproducible_JJ ._SENT Less_JJR variation_NN in_IN mean_JJ MICs_NNS was_VBD found_VBN for_IN all_DT methods_NNS for_IN amoxicillin-clavulanic_JJ acid_NN (_( 0.7_CD to_TO 1.2_CD mug/ml_NN )_) ,_, which_WDT was_VBD one_CD of_IN the_DT most_RBS reproducible_JJ agents_NNS tested_VBN ,_, than_IN for_IN cefprozil_NN (_( 2.7_CD to_TO 9.5_CD mug/ml_NN )_) ,_, which_WDT was_VBD one_CD of_IN the_DT least_JJS reproducible_JJ agents_NNS tested_VBD ._SENT Less_JJR variation_NN in_IN ranges_NNS of_IN mean_JJ +-_NN 2_CD standard_NN error_NN values_NNS (_( approximate_JJ 95_CD %_NN confidence_NN limits_NNS )_) was_VBD also_RB noted_VBN for_IN amoxicillin-clavulanic_JJ acid_NN (_( approximately_RB 1.5_CD doubling_NN dilutions_NNS )_) than_IN for_IN cefprozil_NN (_( approximately_RB 2.5_CD doubling_NN dilutions_NNS )_) ._SENT Figure_NN provides_VBZ a_DT graphical_JJ example_NN of_IN these_DT better_JJR and_CC worse_JJR degrees_NNS of_IN agreement_NN ,_, with_IN confidence_NN intervals_NNS included_VBD ._SENT Despite_IN the_DT differences_NNS in_IN ranges_NNS of_IN variation_NN ,_, the_DT patterns_NNS of_IN variability_NN are_VBP strikingly_RB similar_JJ ._SENT In_IN addition_NN ,_, it_PP is_VBZ possible_JJ to_TO see_VB more_RBR clearly_RB the_DT similarities_NNS within_IN sites_NNS and_CC the_DT differences_NNS among_IN them_PP ._SENT In_IN addition_NN to_TO the_DT differences_NNS with_IN gemifloxacin_NN and_CC grepafloxacin_NN in_IN MH_NP LHB_NP NAD_NN ,_, the_DT only_RB other_JJ discernible_JJ medium_NN differences_NNS were_VBD with_IN amoxicillin_NN and_CC doxycycline_NN for_IN IsoSensitest-based_JJ medium_NN results_NNS ._SENT Amoxicillin_NP IST_NP HTM_NP varied_VBD most_JJS compared_VBN with_IN other_JJ media_NNS (_( +6_NN to_TO -4_CD dilution_NN difference_NN from_IN the_DT frozen_JJ reference_NN )_) ._SENT The_DT amoxicillin_NP IST_NP HTM_NP results_NNS were_VBD lower_JJR by_IN one_CD to_TO two_CD dilutions_NNS at_IN MICs_NP above_IN 8_CD mug/ml_NN ._SENT Doxycycline_NP IST_NP HTM_NP results_NNS were_VBD one_CD to_TO two_CD dilutions_NNS higher_JJR than_IN other_JJ medium_NN results_NNS ,_, and_CC the_DT doxycycline_NN IST_JJ LHB_NP NAD_NN results_NNS were_VBD also_RB slightly_RB higher_JJR by_IN approximately_RB one_CD dilution_NN ._SENT Overall_RB ,_, the_DT results_NNS for_IN different_JJ media_NNS were_VBD comparable_JJ within_IN each_DT testing_NN laboratory_NN ._SENT The_DT results_NNS for_IN site_NN 2_CD and_CC site_NN 3_CD were_VBD slightly_RB lower_RBR overall_JJ than_IN those_DT for_IN site_NN 1_CD ._SENT GEE_NN methodology_NN examined_VBD the_DT effects_NNS of_IN testing_NN sites_NNS and_CC methods_NNS compared_VBN to_TO the_DT baseline_NN of_IN site_NN 1_CD MH_NP HTM_NP ,_, providing_VBG an_DT estimated_JJ regression_NN coefficient_NN for_IN each_DT individual_JJ effect_NN variable_NN ._SENT This_DT coefficient_NN ,_, stated_VBN as_IN the_DT number_NN of_IN doubling_VBG dilutions_NNS from_IN the_DT baseline_NN ,_, describes_VBZ the_DT degree_NN of_IN shift_NN from_IN the_DT baseline_NN caused_VBN by_IN the_DT specified_JJ variable_NN ._SENT These_DT coefficients_NNS and_CC the_DT statistical_JJ significances_NNS of_IN the_DT differences_NNS are_VBP summarized_VBN in_IN Table_NP ._SENT Site_NN 2_CD and_CC PML_NP HTM_NP were_VBD both_DT significant_JJ contributors_NNS to_TO differences_NNS seen_VBN with_IN cefaclor_NN and_CC cefprozil_NN ,_, with_IN shifts_NNS in_IN MICs_NNS of_IN greater_JJR than_IN one_CD doubling_NN dilution_NN for_IN both_DT drugs_NNS ._SENT The_DT site_NN 2_CD coefficient_NN was_VBD greater_JJR than_IN one_CD dilution_NN lower_JJR than_IN the_DT frozen_JJ standard_NN for_IN both_DT drugs_NNS ,_, while_IN the_DT PML_NP HTM_NP coefficient_NN shifted_VBD the_DT MICs_NN greater_JJR than_IN one_CD dilution_NN higher_JJR than_IN the_DT standard_NN for_IN both_DT drugs_NNS ._SENT The_DT quinolones_NNS (_( except_IN for_IN gemifloxacin_NN and_CC ciprofloxacin_NN )_) and_CC macrolides_NNS (_( except_IN for_IN clarithromycin_NN )_) were_VBD also_RB shifted_VBN nearly_RB one_CD dilution_NN lower_JJR with_IN the_DT MH_NP HTM_NP than_IN with_IN the_DT frozen_JJ medium_NN ._SENT Statistically_RB significant_JJ (_( P_NN <_0.05) 90_CD %_NN of_IN endpoints_NNS on_IN scale_NN TABLE_NP 2_CD |_SYM GEE_NP results_NNS ;_: estimated_JJ regression_NN coefficients_NNS and_CC statistical_JJ values_NNS of_IN significance_NN for_IN comparison_NN to_TO standard_JJ TABLE_NP 3_CD |_SYM Paired_JJ t_NN test_NN P_NN value_NN results_NNS within_IN sites_NNS ,_, with_IN results_NNS of_IN MH_NP HTM_NP for_IN each_DT site_NN as_IN standard_JJ TABLE_NP 4_CD |_SYM Paired_JJ t_NN test_NN P_NN value_NN results_NNS of_IN MH_NP HTM_NP results_NNS between_IN sites_NNS TABLE_NP 5_CD |_SYM Paired_JJ t_NN test_NN P_NN value_NN results_NNS for_IN LHB-supplemented_JJ media_NNS TABLE_NP 6_CD |_SYM Percentages_NP of_IN MICs_NP within_IN one_CD or_CC two_CD dilutions_NNS from_IN reference_NN method_NN based_VBN on_IN test_NN site_NN and_CC medium_NN The_DT results_NNS of_IN this_DT study_NN indicate_VBP that_IN MICs_NNS of_IN a_DT wide_JJ variety_NN of_IN antimicrobial_JJ agents_NNS for_IN H._NP influenzae_NP can_MD be_VB reproducibly_RB determined_VBN using_VBG several_JJ media_NNS ._SENT Most_JJS variations_NNS in_IN MICs_NP were_VBD due_JJ to_TO site-to-site_NN differences_NNS and_CC not_RB due_JJ to_TO differences_NNS in_IN media_NNS ._SENT The_DT site-to-site_NN differences_NNS ,_, however_RB ,_, did_VBD not_RB significantly_RB impact_VB the_DT susceptibility_NN rates_NNS for_IN the_DT majority_NN of_IN the_DT antimicrobial_JJ agents_NNS tested_VBD ,_, as_RB many_JJ of_IN the_DT differences_NNS occurred_VBD at_IN drug_NN concentrations_NNS below_IN susceptibility_NN breakpoints_NNS (_( Tables_NP and_CC )_) ._SENT However_RB ,_, considerable_JJ variation_NN in_IN the_DT percentages_NNS of_IN isolates_NNS susceptible_JJ to_TO cefprozil_NN and_CC cefaclor_NN occurred_VBD ,_, as_IN the_DT geometric_JJ mean_JJ MICs_NNS were_VBD close_JJ to_TO NCCLS_NP susceptible_JJ breakpoints_NNS ._SENT Less_JJR variation_NN occurred_VBD when_WRB PK-PD_JJ breakpoints_NNS were_VBD used_VBN ._SENT There_EX were_VBD few_JJ significant_JJ differences_NNS as_IN a_DT result_NN of_IN the_DT compositions_NNS of_IN media_NNS ._SENT The_DT results_NNS obtained_VBD using_VBG Mueller-Hinton_NP broth_NN with_IN 2_CD %_NN LHB_NP and_CC 15_CD mug_NN of_IN NAD/ml_NP and_CC IST_NP with_IN 2_CD %_NN LHB_NP and_CC 15_CD mug_NN of_IN NAD/ml_NP were_VBD equivalent_JJ to_TO the_DT results_NNS obtained_VBD using_VBG HTM_NP for_IN determination_NN of_IN the_DT MICs_NN of_IN agents_NNS evaluated_VBN against_IN H._NP influenzae_NP ._SENT However_RB ,_, HTM_NP is_VBZ more_RBR difficult_JJ to_TO manufacture_VB and_CC has_VBZ a_DT short_JJ shelf_NN life_NN at_IN 4C_JJ (_( 4_CD to_TO 6_CD weeks_NNS )_) before_IN the_DT hematin_NN component_NN degrades_VBZ ,_, whereas_IN LHB-containing_NP media_NNS can_MD be_VB kept_VBN for_IN at_IN least_JJS 6_CD months_NNS at_IN 4C_JJ ;_: both_DT media_NNS are_VBP stable_JJ at_IN -20C_NN (_( -_: )_) ._SENT Additional_JJ advantages_NNS of_IN LHB-based_JJ media_NNS are_VBP that_IN endpoints_NNS are_VBP easier_JJR to_TO read_VB and_CC that_IN the_DT same_JJ medium_NN can_MD be_VB used_VBN to_TO test_VB streptococci_NNS ._SENT A_DT necessary_JJ consideration_NN when_WRB examining_VBG data_NNS with_IN a_DT permissible_JJ range_NN of_IN reproducibility_NN difference_NN statistically_RB is_VBZ at_IN what_WP point_VBP a_DT conventionally_RB significant_JJ result_NN is_VBZ scientifically_RB meaningful_JJ ._SENT MIC_JJ tests_NNS are_VBP generally_RB regarded_VBN as_IN being_VBG in_IN agreement_NN when_WRB they_PP are_VBP reproducible_JJ within_IN one_CD doubling_NN dilution_NN ,_, while_IN for_IN statistical_JJ tests_NNS ,_, such_PDT a_DT difference_NN is_VBZ generally_RB considered_VBN highly_RB significant_JJ ;_: there_EX is_VBZ consequently_RB an_DT inherent_JJ tension_NN between_IN what_WP is_VBZ statistically_RB significant_JJ and_CC what_WP is_VBZ scientifically_RB significant_JJ ._SENT For_IN the_DT purposes_NNS of_IN this_DT study_NN ,_, a_DT shift_NN of_IN 0.25-doubling-dilution_NN difference_NN was_VBD regarded_VBN as_IN representing_VBG a_DT scientifically_RB noteworthy_JJ methodological_JJ or_CC site_NN bias_NN ._SENT There_EX appears_VBZ to_TO be_VB a_DT greater_JJR degree_NN of_IN difference_NN between_IN testing_VBG sites_NNS than_IN among_IN methods_NNS within_IN one_CD site_NN ._SENT Sites_NNS 1_CD and_CC 3_CD ,_, for_IN the_DT most_JJS part_NN ,_, had_VBD good_JJ reproducibility_NN across_IN methods_NNS ,_, while_IN site_NN 2_CD showed_VBD more_JJR variability_NN ._SENT This_DT is_VBZ especially_RB apparent_JJ when_WRB looking_VBG at_IN the_DT GEE_NP results_NNS ,_, where_WRB site_NN 2_CD is_VBZ more_RBR frequently_RB a_DT contributor_NN of_IN significant_JJ difference_NN than_IN the_DT other_JJ two_CD sites_NNS ._SENT Site_NN 2_CD shows_NNS a_DT consistent_JJ bias_NN in_IN the_DT negative_JJ direction_NN ,_, suggesting_VBG that_IN the_DT MICs_NN for_IN all_DT drugs_NNS tested_VBN at_IN that_DT site_NN would_MD be_VB consistently_RB lower_JJR than_IN those_DT found_VBN at_IN the_DT other_JJ sites_NNS ._SENT Examination_NN of_IN method-specific_JJ differences_NNS shows_VBZ only_JJ PML_NP HTM_NP to_TO be_VB a_DT significant_JJ contributor_NN of_IN difference_NN ._SENT In_IN contrast_NN to_TO the_DT site_NN 2_CD bias_NN ,_, that_WDT seen_VBN with_IN this_DT medium_NN is_VBZ in_IN the_DT positive_JJ direction_NN ._SENT MICs_NNS with_IN PML_NP HTM_NP broth_NN would_MD be_VB expected_VBN to_TO be_VB higher_JJR than_IN those_DT found_VBN with_IN the_DT other_JJ methods_NNS ._SENT Examination_NN of_IN the_DT MICs_NN of_IN many_JJ of_IN the_DT antimicrobial_JJ agents_NNS tested_VBN by_IN paired_VBN t_NN test_NN remained_VBD consistent_JJ across_IN both_DT methods_NNS and_CC testing_NN sites_NNS ._SENT The_DT quinolones_NNS ,_, while_IN very_RB statistically_RB different_JJ in_IN the_DT comparison_NN between_IN MH_NP HTM_NP and_CC the_DT frozen_JJ standard_NN ,_, did_VBD not_RB differ_VB much_RB in_IN the_DT between-site_NN analysis_NN ,_, the_DT GEE_NP analysis_NN ,_, or_CC when_WRB tested_VBN as_IN population_NN means_NNS ._SENT Because_IN these_DT drugs_NNS are_VBP active_JJ at_IN very_RB low_JJ concentrations_NNS ,_, a_DT difference_NN of_IN one_CD dilution_NN is_VBZ much_RB less_RBR important_JJ than_IN for_IN drugs_NNS with_IN activity_NN at_IN higher_JJR concentrations_NNS and_CC therefore_RB closer_RBR to_TO or_CC crossing_VBG breakpoints_NNS ._SENT The_DT data_NNS adjustment_NN to_TO test_VB robustness_NN and_CC the_DT resulting_VBG loss_NN of_IN statistical_JJ significance_NN reinforced_VBD the_DT data_NNS summarized_VBN in_IN Table_NP ,_, showing_VBG that_IN the_DT groups_NNS ,_, while_IN statistically_RB different_JJ from_IN each_DT other_JJ ,_, largely_RB agree_VBP within_IN the_DT acceptable_JJ range_NN of_IN differences_NNS for_IN antimicrobial_JJ MIC_JJ testing_NN of_IN 95_CD %_NN within_IN one_CD doubling_NN dilution_NN ._SENT The_DT results_NNS of_IN these_DT tests_NNS ,_, as_RB well_RB as_IN the_DT examination_NN of_IN differences_NNS in_IN group_NN means_NNS ,_, suggest_VBP that_IN there_EX is_VBZ a_DT systematic_JJ shift_NN of_IN less_JJR than_IN one_CD dilution_NN difference_NN in_IN several_JJ of_IN the_DT drugs_NNS ._SENT While_IN this_DT is_VBZ within_IN the_DT acceptable_JJ range_NN for_IN reproducibility_NN ,_, it_PP could_MD be_VB problematic_JJ if_IN the_DT shift_NN occurs_VBZ at_IN or_CC near_IN a_DT breakpoint_NN ._SENT TABLE_NN 7_CD |_SYM MIC50_NP and_CC MIC90_NP for_IN each_DT method_NN TABLE_NP 8_CD |_SYM Ranges_NP and_CC mean_VB percentages_NNS of_IN susceptible_JJ isolates_NNS for_IN all_DT methods_NNS based_VBN on_IN NCCLS_NP and_CC PK-PD_JJ breakpoints_NNS 